19 completed. 19 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 19 |
| Phase 2 | 6 | Completed 6 |
Follow Refractory Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Refractory Diffuse Large B-Cell Lymphoma trials Research Report on Refractory Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Completed | Fred Hutchinson Cancer Center | 27 | 2022-12-08 | 2026-09-21 |
| Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab Ociperlimab, Tislelizumab, Rituximab - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Completed | BeiGene | 53 | 2022-04-25 | 2025-09-15 |
| Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy Efineptakin alfa, Tisagenlecleucel, Axicabtagene ciloleucel - Refractory Diffuse Large B-cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | NeoImmuneTech | 17 | 2021-07-29 | 2026-08-10 |
| Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma Duvelisib, Nivolumab - Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | David Bond, MD | 7 | 2019-11-05 | 2024-05-02 |
| Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant Busulfan, Gemcitabine, Melphalan - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 50 | 2019-09-13 | 2026-07-30 |
| A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma INCB053914, INCB050465 - Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | Incyte Corporation | 9 | 2018-12-03 | 2020-11-10 |
| Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma Mogamulizumab, Pembrolizumab - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2018-10-24 | 2023-09-21 |
| Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma Carmustine, Cytarabine, Etoposide - Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 19 | 2018-09-10 | 2025-05-14 |
| Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Avelumab, Carboplatin - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 1 | Completed | City of Hope Medical Center | 16 | 2018-06-08 | 2026-10-02 |
| Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL Ipilimumab, Nivolumab - Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | Icahn School of Medicine at Mount Sinai | 6 | 2018-05-14 | 2023-02-15 |
| Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) Betalutin - Relapsed, Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | Nordic Nanovector | 18 | 2017-03-02 | 2024-01-16 |
| Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Nivolumab - Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma | Phase 1 / Phase 2 | Completed | David Bond, MD | 36 | 2017-02-14 | 2026-09-23 |
| Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pembrolizumab - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Grade 1 Follicular Lymphoma | Phase 1 | Completed | Kami Maddocks | 2 | 2017-01-12 | 2019-07-30 |
| A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects C-CAR-011 - Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | Shanghai AbelZeta Ltd. | 15 | 2016-12-01 | 2019-01-17 |
| Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma Blinatumomab, Lenalidomide - Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 35 | 2016-11-15 | 2025-11-26 |
| Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Carboplatin, Etoposide, Ibrutinib - CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2014-09-12 | 2018-01-26 |
| Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Ibrutinib, Lenalidomide, Rituximab - Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Pharmacyclics LLC. | 138 | 2014-03-13 | 2022-02-04 |
| Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas Alisertib, Laboratory Biomarker Analysis, Romidepsin - MYC Positive, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2013-07-17 | 2019-01-28 |
| Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes - CD19-Positive Neoplastic Cells Present, Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 204 | 2013-05-22 | 2022-05-25 |
Lymphoma, Large B-Cell, Diffuse (19) · Lymphoma, Mantle-Cell (6) · Lymphoma, Follicular (5) · Lymphoma, Non-Hodgkin (5) · Burkitt Lymphoma (4) · Lymphoma, B-Cell, Marginal Zone (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Hodgkin Disease (2) · Lymphoma (2) · Lymphoma, B-Cell (2) · Lymphoma, T-Cell (2) · Neoplasms (2) · Waldenstrom Macroglobulinemia (2) · AIDS-Related Complex (1) · Immune System Diseases (1)
Hemic and Lymphatic Diseases (19) · Immune System Diseases (18) · Immunoproliferative Disorders (18) · Lymphatic Diseases (18) · Lymphoproliferative Disorders (18) · Neoplasms by Histologic Type (18) · Lymphoma (17) · Lymphoma, B-Cell (17) · Neoplasms (17) · Lymphoma, Non-Hodgkin (14) · Hematologic Diseases (5) · Infections (5) · Virus Diseases (5) · DNA Virus Infections (4) · Disease Attributes (4)
Rituximab (5) · ibrutinib (4) · CT-P10 (3) · Lenalidomide (3) · Nivolumab (3) · Carboplatin (2) · Etoposide (2) · Ifosfamide (2) · Melphalan (2) · Stem Cell Transplantation (2) · pembrolizumab (2) · Biopsy (1) · Busulfan (1) · Carmustine (1) · Cyclophosphamide (1)
National Cancer Institute (NCI) (4) · David Bond, MD (2) · Fred Hutchinson Cancer Center (2) · BeiGene (1) · City of Hope Medical Center (1) · Icahn School of Medicine at Mount Sinai (1) · Incyte Corporation (1) · Kami Maddocks (1) · M.D. Anderson Cancer Center (1) · NeoImmuneTech (1) · Nordic Nanovector (1) · Ohio State University Comprehensive Cancer Center (1) · Pharmacyclics LLC. (1) · Shanghai AbelZeta Ltd. (1)
United States (17) · China (2) · Germany (2) · United Kingdom (2) · Belgium (1) · Italy (1) · Spain (1)
David Bond, MD (2) · Kami Maddocks, MD (2) · Alexandre Hirayama (1) · Craig Sauter (1) · Elizabeth Budde (1) · Erel Joffe (1) · Fred Zheng, MD (1) · Hun Lee (1) · Jianyong Li (1) · John DiPersio, M.D. (1) · Jordan Gauthier (1) · Joseph M Tuscano (1) · Joshua Brody, MD (1) · Jutta K. Neuenburg, MD, PhD (1) · Timothy Illidge, PhD MB BS (1)
PMID 34515338, PMID 27111235, PMID 29038338, PMID 29386196, PMID 30728140, PMID 30729531, PMID 30782611, PMID 31331917, PMID 31648294, PMID 32967009, PMID 33786583, PMID 34666344, PMID 36618900, PMID 37774014, PMID 39333103, PMID 41595202, PMID 42389828
P30CA008748 (1), P30CA016058 (1), P30CA016672 (1), P50CA107399 (1), R01CA136551 (1), U01CA062461 (1), UM1CA186644 (1), UM1CA186688 (1), UM1CA186691 (1), UM1CA186717 (1)